<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059537</url>
  </required_header>
  <id_info>
    <org_study_id>SJ-546</org_study_id>
    <nct_id>NCT03059537</nct_id>
  </id_info>
  <brief_title>Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea</brief_title>
  <acronym>VABAD</acronym>
  <official_title>Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Kristian Munck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to validate a possible diagnostic test for bile acid diarrhoea prospectively
      compared to the SeHCAT scintigraphy. Fasting participants are given a standard meal and 1,250
      mg chenodeoxycholic acid. The investigators measure fasting FGF19, bile acids species
      including 7-alpha-CHO and serial blood samples after the stimulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Actual">November 27, 2017</completion_date>
  <primary_completion_date type="Actual">November 27, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative predictive value of stimulated deltaFGF19</measure>
    <time_frame>Individual data are collected within one week</time_frame>
    <description>For screening purposes for bile acid diarrhoea. Negative Predictive Value by Receiver Operating Curve analysis for SeHCAT &lt; 10 %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other diagnostic and Nosographic propabilities stimulated deltaFGF19, SeHCAT &lt; 10%</measure>
    <time_frame>Individual data are collected within one week</time_frame>
    <description>Positive predictive value, sensitivity and specificity for bile acid diarrhoea judged by FGF19 for SeHCAT &lt;10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other diagnostic and Nosographic propabilities stimulated deltaFGF19, SeHCAT &lt; 5%</measure>
    <time_frame>Individual data are collected within one week</time_frame>
    <description>Positive predictive value, sensitivity and specificity for bile acid diarrhoea judged by FGF19 for SeHCAT &lt;5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic and Nosographic propabilities of 7alpha-CHO for SeHCAT &lt;10%</measure>
    <time_frame>Individual data are collected within one week</time_frame>
    <description>Positive predictive value, sensitivity and specificity for bile acid diarrhoea judged by 7alpha-CHO for SeHCAT &lt;10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic and Nosographic propabilities of 7alpha-CHO for SeHCAT &lt;5%</measure>
    <time_frame>Individual data are collected within one week</time_frame>
    <description>Positive predictive value, sensitivity and specificity for bile acid diarrhoea judged by 7alpha-CHO for SeHCAT &lt;5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of FGF19 to clinical diarrhoea</measure>
    <time_frame>Individual data are collected within one week</time_frame>
    <description>Correlation of FGF19 (fasting and stimulated deltaFGF19) to diarrhoea by stool diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of 7alpha-CHO to clinical diarrhoea</measure>
    <time_frame>Individual data are collected within one week</time_frame>
    <description>Correlation of fasting 7alpha-CHO to diarrhoea by stool diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FGF19 by SeHCAT stratum</measure>
    <time_frame>Individual data are collected within one week</time_frame>
    <description>Median stimulated ∆FGF19 in SeHCAT stratum: 0-5%, &gt;5.1-10%, &gt;10.1-15%, &gt; 15.1%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7alpha-CHO by SeHCAT stratum</measure>
    <time_frame>Individual data are collected within one week</time_frame>
    <description>Median fasting 7alpha-CHO in SeHCAT stratum: 0-5%, &gt;5.1-10%, &gt;10.1-15%, &gt; 15.1%.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Bile Acid Malabsorption</condition>
  <arm_group>
    <arm_group_label>Stimulation Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study meal plus chenodeoxycholic acid: 1,250 mg single dose stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral chenodeoxycholic acid stimulation</intervention_name>
    <description>oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor</description>
    <arm_group_label>Stimulation Test</arm_group_label>
    <other_name>Chenodeoxycolic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Consecutive patients referred for SeHCAT

        Exclusion Criteria:

          -  Treatment with sequestrants within one week before the SeHCAT.

          -  Treatment with any constipants/laxatives one day before the SeHCAT, with the exception
             of opioids, if the dosis has been stable in the prior 2 weeks.

          -  Pregnancy, screening by pregnancy test before inclusion.

          -  Breastfeeding women.

          -  Small bowel resection, including right sided hemicolectomy.

          -  Any ongoing treatment for inflammatory bowel disease with systemic steroids (i.e.
             budesonide or prednisone) or treatment in the prior 4 weeks.

          -  Allergies to constituents of Xenbilox: (chenodeoxycholic acid, cornflour, magnesium
             stearate, highly dispersed silica, gelatine, sodium dodecylsulphate, titanium dioxide
             (E171), quinolone yellow (E104), erythrosine (E127)

          -  Chronic or acute cholecystitis.

          -  Liver cirrhosis,

          -  Obstructed bile flow causing jaundice or elevated p-bilirubin (&gt; 1,5 UNL).

          -  Known disability in gall bladder contractility.

          -  Bile duct atresia.

          -  Frequent gallstone attacks (&gt;2/month).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Borup, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zealand University Hopsital</name>
      <address>
        <city>Holbaek</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zealand University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Kristian Munck</investigator_full_name>
    <investigator_title>DMSci</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Malabsorption Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Acids and Salts</mesh_term>
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

